华仁药业, Huaren Pharmaceutical 
 华仁药业股份有限公司（简称华仁药业）成立于1998年5月，2001年8月完成股份制改造，是专业生产非PVC软袋输液的高新技术企业。公司是由华仁世纪集团控股，红塔创新投资控股有限公司、广发信德投资股份有限公司、中国药科大学等国内知名企业、院校参股的集产、学、研一体的新型股份公司。公司注册资本2.183635亿元，总资产12.4748亿元，公司拥有普通型输液、治疗型输液、营养型输液三大类产品，共有二十七个品种、六十七个规格的产品成功上市。2010年8月25日，公司在深圳证券交易所创业板正式挂牌上市，首次公开发行股票5360万股，股票简称“华仁药业”，股票代码为“300110”。

公司位于青岛市高科技工业园西北侧，毗邻海尔工业园、惠特工业园和崂山风景度假区，风景秀丽，空气清新，水源来自崂山地下水，水质优良，符合制药厂的环境及水源要求。公司占地面积5.9万平方米，一期工程建筑面积1.36万平方米，二期工程建筑面积2.08万平方米。厂区布局合理，绿化优良。

公司一期工程是由国际著名医药工程建设公司意大利STERIL公司设计、安装、调试并实施“交钥匙工程”。1998年公司从欧洲引进了世界最先进的制水、配液、制袋灌封、灭菌等核心生产设备，保证了产品品质的领先优势；双室袋生产线的引进，更是填补了国内空白。

随着市场的不断增长，华仁药业二期工程于2008年4月5日开工，并于2009年8月27日整体通过国家GMP认证；该工程拥有国内同行业最先进的自动化生产线，以及一个全自动的现代化立体仓库，它的投产成功是华仁药业发展史上的又一个里程碑；二期工程的建成使我们不但拥有了近亿的产能，更增强了我们的产品在质量和成本上的市场竞争力。

医药行业是关系国计民生的大行业，是一个决不允许出现劣质不安全产品的行业；正是本着这样一种对生命健康负责的态度，公司秉持“健康从点滴做起”的企业精神，实施全员、全方位、全过程的质量管理；坚持“健康、环保、安全”的生产理念，严格按照国家GMP标准及SFDA要求，对人员、设备、仪器、工艺方法、环境等进行全方位的验证、管理和控制，并从原料、中间品到成品全过程进行物理、化学、生物学的检测、管理和控制，达到美国FDA、欧洲药典标准和国家标准，处于国内领先水平。

在研发方面，公司新扩建的研发中心研发的附加值极高、市场适用性与竞争力较强的腹膜透析液、脂肪乳、氨基酸、代血浆、肠外营养双室袋等非PVC软包装输液项目也取得了可喜的进展与突破。

公司还坚持管理创新、技术创新、服务创新，积极推进和实施ERP系统的建设，以优化工作流程，提高工作效率。凭借着卓越的产品质量和完善的售后服务，公司产品被客户广泛接受和认可，产品成功进入北京、上海、广东、南京、浙江、湖北、山东、东北三省等全国26个省市；全国已建立了12个销售中心，在全国非PVC软袋输液市场占有率居前三甲。

经过十余年的发展，公司先后取得了“国家重点技术改造‘双高一优’项目”、“全国AAA级信誉企业”、“山东省质量管理奖”、“山东省著名商标”、“山东省守合同重信用企业”、“2008青岛市最具有成长型中小企业”、“青岛市改革开放三十年风云企业”、“建国六十周年山东省医药行业卓越企业”、“2009年消防安全工作先进单位”、“2009年度红十字博爱银奖”、“2009年度中国诚信企业”、“2010年度红十字博爱银奖”、“2011年度消防工作先进单位”、第三届中国优秀医院服务商品牌“金如意奖”、“中国驰名商标”等一系列荣誉，被福布斯评为“2009福布斯最具潜力中小企业”，并成为中国人民解放军总后勤部、卫生部应急储备的定点输液生产企业。

作为专业生产非PVC软袋输液的高新技术企业，华仁药业以改善人类“后健康”为己任，秉承“输液质量肩负生命之托，责任重于泰山”的企业理念，用安全、优质的输液产品和完善的客户服务回报社会，致力于打造国内一流的非PVC输液生产基地。

Qingdao Huaren Pharmaceutical Corp.(briefly as Huaren) was founded in May of 1998 and finished its shareholding reform in August of 2001. It is a new high-tech enterprise which is a professional manufacturer of Non-PVC I.V. solution. It is one modern-style joint-stock company covering the production, marketing and R&D of I.V. Solution. The holding company is Qingdao Huaren Group Ltd., enterprises such as HongTa Innovation Investment Co., Ltd., Guangfa Xinde investment Co., LTD and China Pharmaceutical University etc. take the share of Huaren. The company has registered capital of 160 million yuan and permanent assets of 600 million yuan. There are three kinds of injection, conventional injection, therapeutic injection, nutritious injection, with products of 27 kinds and 57 specifications in the market.
The company is located in the northwest of Qingdao High-Tech Industrial Park, adjoins to Haier Industrial Park, Whitt Industrial Garden and Mt. Laoshan scenic spot, with beautiful scenery, fresh air and groundwater resources from Mt. Laoshan which conforms to pharmaceutical manufacturing environment and water resource requirement. The company covers an area of 59,000 square meters, the first stage construction covers an area of 13,600 square meters, and 20,800 square meters for second stage construction. The layout is reasonable and the afforestation is fine.
The first stage construction was totally designed and constructed by STERIL, a famous international medical project-construction corporation in Italy, and carried out the turn-key project. In 1998, Huaren imported its nucleus equipments for water making, solution making, bag making-filling and inspection from Europe; the introduction of double chamber bag production line fills the blank in China.
As the enlargement of market need, Huaren started the second stage construction on April 5th 2008, and passed the State GMP certificate on August 27th 2009. There are the most advanced production lines in the State, and full automated overhead warehouse in the new factory. Its going into production is a milestone in Huaren’s development. After finishing the second stage construction, we have capacity of around 100million bags. It strengthens our competitive strength on production cost and quality in the market.
Pharmaceuticals industry has respect to the national economy and the people's livelihood, should not have any product of inferior quality. Maintaining a high sense of responsibility to lives, the company insists the management philosophy of “Keep Healthy start from dribs and drabs”, and carries out quality control on departmental and overall process, insisting the faith of “Environment-Friendly，Healthy and Safety”. According to Country GMP and SFDA Standards of management, the company carried on omnibearing confirmation, management and control on personnel, equipments, instruments and techniques, environment and so on. Carrying on physical, chemistry and biology examination from raw materials to end production, it reaches the requirements of American FDA, European pharmacopoeia standard and national standards, leading in the state.
On research and development, in the new research and development centre, we have made significant progress and breakthrough in some Non-PVC I.V. solution programs with highly added value and competitive strength in the market, such as fat emulsions, amino acids, and dextran, parenteral nutrition double-chamber bags. Among these programs, the fat emulsions program has finished all study of pharmacy, and has reported to SFDA. Organ preservation and combination connection of Non-PVC I.V. solution bag have already declared the invention patent with proprietary intellectual property rights to the State.